346 related articles for article (PubMed ID: 24880945)
1. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
Chen G; Davies MA
Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for melanoma: rational combinatorial approaches.
Kwong LN; Davies MA
Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
4. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
5. A new standard of care for metastatic melanoma?
Sharma SP
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
[No Abstract] [Full Text] [Related]
6. Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.
Lo RS; Shi H
Methods Mol Biol; 2014; 1102():163-74. PubMed ID: 24258979
[TBL] [Abstract][Full Text] [Related]
7. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
8. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
[TBL] [Abstract][Full Text] [Related]
9. Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.
Johnpulle RA; Johnson DB; Sosman JA
Curr Oncol Rep; 2016 Jan; 18(1):6. PubMed ID: 26743513
[TBL] [Abstract][Full Text] [Related]
10. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
[TBL] [Abstract][Full Text] [Related]
12. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
Cohen JV; Sullivan RJ
Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
[TBL] [Abstract][Full Text] [Related]
13. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
14. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
15. BRAF in melanoma: current strategies and future directions.
Salama AK; Flaherty KT
Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatment for BRAF-mutant melanoma: where do we go next?
Menzies AM; Long GV
Lancet Oncol; 2014 Aug; 15(9):e371-81. PubMed ID: 25079100
[TBL] [Abstract][Full Text] [Related]
17. BRAF inhibitors in cancer therapy.
Hertzman Johansson C; Egyhazi Brage S
Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
[TBL] [Abstract][Full Text] [Related]
18. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.
Dummer R; Flaherty KT
Curr Opin Oncol; 2012 Mar; 24(2):150-4. PubMed ID: 22316627
[TBL] [Abstract][Full Text] [Related]
19. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
Seghers AC; Wilgenhof S; Lebbé C; Neyns B
Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
